Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.82, $0.02 better than the analyst estimate of $0.80. Revenue for the quarter came in at $230 million versus the consensus estimate of $232 million.

GUIDANCE:

Halozyme Therapeutics sees FY2024 EPS of $3.55-$3.90, versus the consensus of $3.64. Halozyme Therapeutics sees FY2024 revenue of $915-985 million, versus the consensus of $961.1 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.